<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis, clinical manifestations, and diagnosis of pemphigus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Hertl, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cassian Sitaru, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John J Zone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H181681324"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pemphigus is defined as a group of life-threatening blistering disorders characterized by acantholysis (loss of keratinocyte to keratinocyte adhesion) that results in the formation of intraepithelial blisters in mucous membranes and skin [<a href="#rid1">1</a>]. The process of acantholysis is induced by the binding of circulating immunoglobulin G (IgG) autoantibodies to intercellular adhesion molecules [<a href="#rid1">1-3</a>]. Patients with pemphigus develop mucosal erosions and/or flaccid bullae, erosions, or pustules on skin.</p><p>The four major entities of the pemphigus group include pemphigus vulgaris, pemphigus foliaceus, immunoglobulin A (IgA) pemphigus, and paraneoplastic pemphigus. The different forms of pemphigus are distinguished by their clinical features, associated autoantigens, and laboratory findings [<a href="#rid4">4,5</a>].</p><p>The pathogenesis, clinical features, and diagnosis of pemphigus will be discussed here. The management of pemphigus and greater detail on paraneoplastic pemphigus are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus"</a> and  <a class="medical medical_review" href="/z/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a> and  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p class="headingAnchor" id="H460257"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Common features of the major types of pemphigus are reviewed briefly below. A broader summary of the clinical and laboratory features of pemphigus is provided in the table  (<a class="graphic graphic_table graphicRef87920" href="/z/d/graphic/87920.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus vulgaris</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Key features </strong>–<strong> </strong>Mucosal or mucosal and cutaneous involvement, suprabasal acantholytic blisters, IgG autoantibodies against desmoglein 3 or both desmoglein 1 and desmoglein 3</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical variants </strong>– Pemphigus vegetans, pemphigus herpetiformis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus foliaceus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Key features</strong> –<strong> </strong>Cutaneous involvement only, subcorneal acantholytic blisters, IgG autoantibodies against desmoglein 1</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical variants</strong> – Endemic pemphigus foliaceus (fogo selvagem), pemphigus erythematosus (Senear-Usher syndrome), pemphigus herpetiformis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgA pemphigus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subtypes</strong> – Subcorneal pustular dermatosis-type IgA pemphigus (distinct from classic subcorneal pustular dermatosis [Sneddon-Wilkinson disease]), intraepidermal neutrophilic IgA dermatosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Key features</strong> – Grouped vesicles or pustules and erythematous plaques with crusts, subcorneal or intraepidermal acantholytic blisters, autoantibodies against desmocollin 1 in subcorneal pustular dermatosis-type IgA pemphigus [<a href="#rid6">6</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic pemphigus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Key features</strong> –<strong> </strong>Extensive, intractable stomatitis and variable cutaneous findings with multiform exanthems, associated neoplastic disease, suprabasal acantholytic blisters, autoantibodies against desmoplakins or other desmosomal antigens (see  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>)</p><p></p><p class="headingAnchor" id="H181679697"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Pemphigus vulgaris, which represents the most common form of pemphigus, is a rare disease. Although pemphigus vulgaris occurs worldwide, the frequency is influenced by geographic location and ethnicity. Incidence rates between 0.1 and 0.5 per 100,000 people per year have been reported most frequently; however, higher rates have been documented in certain populations [<a href="#rid7">7</a>]. Individuals with Jewish ancestry (particularly Ashkenazi Jews) and inhabitants of India, Southeast Europe, and the Middle East have the greatest risk for pemphigus vulgaris [<a href="#rid8">8</a>].</p><p>In most geographic locations, pemphigus vulgaris is more common than pemphigus foliaceus. However, in certain locations, such as North Africa and South America, the prevalence of pemphigus foliaceus exceeds pemphigus vulgaris [<a href="#rid9">9</a>]. Endemic pemphigus foliaceus (fogo selvagem) contributes to the higher rate of pemphigus foliaceus in some of these countries. In an endemic region in the state of Mato Grosso do Sul in Brazil, the prevalence of pemphigus foliaceus during the mid-1990s was around 3 percent [<a href="#rid10">10</a>]. An endemic form of pemphigus vulgaris also has been reported in a small number of patients residing in an endemic region of pemphigus foliaceus in Brazil [<a href="#rid11">11</a>].</p><p>Pemphigus usually occurs in adults, with an average age of onset of 40 to 60 years for pemphigus vulgaris and nonendemic pemphigus foliaceus [<a href="#rid12">12,13</a>]. Pemphigus is rare in children, with the exception of endemic pemphigus foliaceus, which frequently affects children and young adults in endemic areas [<a href="#rid14">14</a>]. Neonatal pemphigus is a rare transient form of pemphigus that occurs as a consequence of placental transmission of autoantibodies to the fetus from a mother with the disease. (See <a class="local">'Neonatal pemphigus'</a> below.)</p><p>Overall, the sex ratio for pemphigus vulgaris and pemphigus foliaceus appears to be equivalent or close to equivalent [<a href="#rid15">15</a>]. However, a few studies have found large imbalances in the sex distribution, such as a study that found a 4:1 ratio of females to males with pemphigus foliaceus in Tunisia [<a href="#rid16">16</a>] and a study that found a 19:1 ratio of males to females in an endemic location in Colombia [<a href="#rid17">17</a>].</p><p>Epidemiologic information on IgA pemphigus is sparse. The disorder may occur at any age and may be slightly more common in females [<a href="#rid6">6</a>]. Paraneoplastic pemphigus is rare. The disorder is most commonly seen in middle-aged adults, but may also occur in children. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H181679704"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H20089722"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Intensive investigations to elucidate the pathogenesis of pemphigus have led to wide acceptance of the theory that acantholysis induced by the binding of autoantibodies to epithelial cell surface antigens leads to the clinical manifestations of pemphigus [<a href="#rid2">2,18,19</a>]. This theory is supported by the consistent detection of intercellular autoantibodies in perilesional tissue from patients with pemphigus  (<a class="graphic graphic_picture graphicRef82837 graphicRef82838" href="/z/d/graphic/82837.html" rel="external">picture 1A-B</a>) (see <a class="local">'Diagnosis'</a> below). Experimental findings that offer further support include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In vitro studies have demonstrated that IgG autoantibodies from patients with pemphigus vulgaris, pemphigus foliaceus, and IgA pemphigus are capable of inducing loss of epidermal cohesion [<a href="#rid20">20-23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In vivo studies have shown that the passive transfer of IgG autoantibodies from patients with pemphigus vulgaris into neonatal mice induces blistering and erosions with histologic, ultrastructural, and immunofluorescence features consistent with pemphigus [<a href="#rid24">24,25</a>]. The blister-inducing potential of IgG autoantibodies in pemphigus foliaceus and paraneoplastic pemphigus has been demonstrated in similar in vivo mouse studies [<a href="#rid26">26-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Removal of serum autoantibodies from patients with pemphigus vulgaris or pemphigus foliaceus via antigen-specific immunoadsorption prior to injection into neonatal mice prevents blistering in injected neonatal mice [<a href="#rid29">29,30</a>].</p><p></p><p>The molecular mechanisms through which binding of autoantibodies to epithelial cells leads to acantholysis are still intensively debated. Several mechanisms for antibody-mediated acantholysis have been proposed, including the induction of signal transduction events that trigger cell separation and the inhibition of adhesive molecule function through steric hindrance [<a href="#rid2">2,31,32</a>]. In particular, the theory of apoptolysis suggests that acantholysis results from autoantibody-mediated induction of cellular signals that trigger enzymatic cascades that lead to structural collapse of cells and cellular shrinkage [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H181679711"><span class="h2">Target antigens</span><span class="headingEndMark"> — </span>Autoantibodies against a variety of epithelial cell surface antigens, intracellular and transmembranous components of desmosomes, have been identified in patients with pemphigus.</p><p class="headingAnchor" id="H106828057"><span class="h3">Pemphigus vulgaris and pemphigus foliaceus</span><span class="headingEndMark"> — </span>Desmogleins, which are transmembrane glycoproteins of the cadherin (calcium-dependent cell adhesion molecule) family, are the antigens that have been most extensively studied in pemphigus vulgaris and pemphigus foliaceus. Desmogleins are components of desmosomes, integral structures for cell-to-cell adhesion  (<a class="graphic graphic_figure graphicRef87355" href="/z/d/graphic/87355.html" rel="external">figure 1</a>).</p><p>IgG autoantibodies to desmogleins are consistently detected via enzyme-linked immunosorbent assay (ELISA) in patients with pemphigus, and the expression of these autoantibodies often correlates with the type of disease [<a href="#rid34">34,35</a>]. IgG autoantibodies against <strong>desmoglein 3</strong> are characteristic of <strong>mucosal pemphigus vulgaris</strong>, autoantibodies against <strong>desmoglein 1 </strong>have been linked to<strong> pemphigus foliaceus</strong>, and autoantibodies to <strong>desmoglein 1 and desmoglein 3 </strong>have been linked to mucocutaneous <strong>pemphigus vulgaris</strong>. The amino-terminal portions of desmogleins appear to be the important epitopes for pathogenicity as evidenced by studies that demonstrate that IgG directed against an amino-terminal recombinant fraction of desmoglein 3 (EC1-2) induces epithelial blistering when injected into neonatal mice or exposed to cultured human skin [<a href="#rid36">36,37</a>]. Findings demonstrate that IgG against the carboxy-terminal EC5 subdomain is also capable of inducing loss of cell-cell adhesion, presumably via mitogen-activated protein kinase (MAPK)-dependent signaling [<a href="#rid38">38</a>].</p><p>IgG autoantibodies considered to be pathogenic are of the immunoglobulin G4 (IgG4) subclass [<a href="#rid25">25,37,39,40</a>]. However, desmoglein-specific IgG autoantibodies may also belong to other isotypes. Emerging evidence suggests that other IgG subclasses, such as immunoglobulin G3 (IgG3), may have a pathogenic effect and that the diversity of the desmoglein 3-specific IgG subclasses impacts both disease activity and relapse risk [<a href="#rid41">41</a>].</p><p>In the 1990s, the <strong>desmoglein compensation theory</strong> was proposed as an explanation for the observed correlation between the clinical features and autoantibody profiles of pemphigus vulgaris and pemphigus foliaceus [<a href="#rid42">42</a>]. Although the theory is still widely cited, subsequent data has raised questions about whether this concept sufficiently explains the pathogenic mechanism of these diseases [<a href="#rid43">43</a>].</p><p>According to the desmoglein compensation theory, the correlation between clinical findings and ELISA results reflects innate differences in desmoglein expression in the skin and mucous membranes [<a href="#rid42">42</a>]. In the skin, desmoglein 1 is expressed most intensely in the upper portions of the epidermis, whereas desmoglein 3 is more strongly expressed in the basal and parabasal layers. In the mucous membranes, desmoglein 3 is present in abundance throughout the epithelium. In contrast, the expression of desmoglein 1 is much lower throughout the mucosal epithelium  (<a class="graphic graphic_figure graphicRef87356" href="/z/d/graphic/87356.html" rel="external">figure 2</a>).</p><p>The interpretation of this theory as it relates to the clinical findings in pemphigus is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <strong>only autoantibodies against desmoglein 3 </strong>should have<strong> mucosal dominant pemphigus vulgaris</strong> because in skin, desmoglein 1 compensates for the loss of desmoglein 3. In the mucous membranes, the expression of desmoglein 1 is insufficient for compensation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <strong>only </strong>autoantibodies against <strong>desmoglein 1</strong> should have <strong>pemphigus foliaceus</strong> (superficial skin blistering and no mucous membrane involvement) because autoantibodies against desmoglein 1 result in separation of cells in the superficial epithelium, but not in the deeper epithelium, where desmoglein 3 compensates well for desmoglein 1 dysfunction. The mucous membranes are spared due to the high levels of desmoglein 3 and the relatively low levels of desmoglein 1 expressed in mucosa.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <strong>both </strong>autoantibodies against <strong>desmoglein 1 and 3</strong> should have <strong>mucocutaneous pemphigus vulgaris</strong> because dysfunction of both desmoglein 1 and 3 prevents the ability of these glycoproteins to compensate for one another, resulting in a loss of cell-cell adhesion in both skin and mucous membranes.</p><p></p><p>However, it is likely that the pathogenesis of pemphigus is more complex than this model predicts. Discordance between the clinical and serologic profiles (eg, patients with pemphigus foliaceus who have autoantibodies against desmoglein 3, patients with pure mucosal pemphigus vulgaris who have autoantibodies against desmoglein 1, and patients with pemphigus who have neither autoantibodies against desmoglein 1 nor autoantibodies against desmoglein 3) may occur in about one-third of cases [<a href="#rid43">43,44</a>]. This observation and the knowledge that the presence of IgG autoantibodies to both desmoglein 1 and desmoglein 3 does not result in complete dissolution of the epithelium suggest that additional factors contribute to the development of these diseases.</p><p>Autoantibodies against desmocollin 3 may contribute to pemphigus in some patients. Like desmogleins, desmocollins are transmembrane glycoproteins found within desmosomes  (<a class="graphic graphic_figure graphicRef87355" href="/z/d/graphic/87355.html" rel="external">figure 1</a>). Desmocollin 3-specific autoantibodies from patients with pemphigus have induced loss of keratinocyte adhesion ex vivo and in experimental animals [<a href="#rid45">45,46</a>]. Moreover, a subset of patients with clinical features most consistent with pemphigus herpetiformis or pemphigus vegetans and direct immunofluorescence findings consistent with pemphigus who have autoantibodies against desmocollin but no autoantibodies against desmoglein has been identified [<a href="#rid47">47,48</a>]. A study has shown that IgG against desmocollin-3 induces loss of cell-cell adhesion in vitro and in vivo. This process also involves MAPK-dependent signaling [<a href="#rid38">38</a>].</p><p>Additional autoantibodies detected in serum from patients with pemphigus include autoantibodies against desmoglein 4, the acetylcholine receptor, pemphaxin, and others [<a href="#rid33">33,49-53</a>]. Whether autoantibodies with any of these molecular specificities are pathogenic in pemphigus vulgaris or pemphigus foliaceus remains to be determined.</p><p class="headingAnchor" id="H106828447"><span class="h3">IgA pemphigus</span><span class="headingEndMark"> — </span>Unlike the other forms of pemphigus, which are characterized by IgG autoantibodies targeting epithelial cell surface antigens, IgA pemphigus is characterized by antikeratinocyte cell surface autoantibodies of the IgA class [<a href="#rid54">54</a>]. The target antigen in the <strong>subcorneal pustular dermatosis type of IgA pemphigus </strong>is <strong>desmocollin 1</strong>, a transmembrane glycoprotein within desmosomes [<a href="#rid55">55-57</a>].</p><p>In contrast, the targeted antigens in the intraepidermal neutrophilic dermatosis variant of IgA pemphigus appear to be more heterogeneous. While autoantibodies against desmogleins 1 and 3 have been reported in several patients [<a href="#rid56">56,58-60</a>], immunoelectron microscopy studies suggest that IgA autoantibodies in these patients recognize an unidentified non-desmosomal transmembranous protein [<a href="#rid61">61</a>]. Thus, a common autoantigen remains elusive and the mechanism of blister formation in IgA pemphigus is not fully understood [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H20091011"><span class="h3">Paraneoplastic pemphigus</span><span class="headingEndMark"> — </span>Multiple autoantibodies have been detected in patients with paraneoplastic pemphigus. The target antigens for this variant are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus", section on 'Humoral immunity'</a>.)</p><p class="headingAnchor" id="H458450"><span class="h2">Contributing factors</span><span class="headingEndMark"> — </span>As with many other autoimmune diseases, the precipitating factors of pemphigus diseases are poorly understood. Both genetic and environmental factors may influence the development of pemphigus [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H458457"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>Multiple studies have evaluated the relationship between pemphigus vulgaris and pemphigus foliaceus with human leukocyte antigen (HLA) class II alleles. Pemphigus vulgaris is associated with DR4 and DR14, though the susceptibility gene differs dependent upon ethnic origin. HLA-DRB1 0402 is associated with the disease in Ashkenazi Jews [<a href="#rid62">62,63</a>], and DRB1 1401/04 and DQB1 0503 have been associated with pemphigus vulgaris in some other populations [<a href="#rid64">64-69</a>]. Sporadic and endemic pemphigus foliaceus are also associated with DR4, DR14, and DR1 alleles [<a href="#rid9">9</a>].</p><p>In contrast to pemphigus vulgaris, the association with HLA alleles in pemphigus foliaceus is less restricted. DRB1 0402, 0403, 0404, 0406, 1401, 1402, 1406, and 0102 subtypes have been detected at increased frequency in patients with pemphigus foliaceus, while DRB1 0301, 0701, 0801, 1101, 1104, and 1402 are negatively associated with this disease [<a href="#rid70">70-73</a>].</p><p>The involvement of genetic factors in susceptibility to pemphigus is further strengthened by detection of low titers of desmoglein 3-specific autoantibodies in asymptomatic relatives of patients with both pemphigus vulgaris and foliaceus [<a href="#rid11">11,74</a>]. In addition, a case-control study found that compared with relatives of healthy controls, first-degree family members of patients with pemphigus had an increased prevalence of autoimmune diseases [<a href="#rid62">62</a>]. The findings of one study suggest that pemphigus vulgaris clusters with autoimmune thyroid disease, rheumatoid arthritis, and type 1 diabetes in patients and their families [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H458464"><span class="h3">Environment</span><span class="headingEndMark"> — </span>While most cases of pemphigus foliaceus are idiopathic, environmental factors appear to contribute in the development of endemic pemphigus foliaceus (fogo selvagem) [<a href="#rid49">49,76</a>]. A black fly (<em>Simulium nigrimanum</em>) or other insects may serve as a vector for the endemic form of this disease [<a href="#rid77">77</a>].</p><p>Ultraviolet radiation has been proposed as an exacerbating factor for pemphigus foliaceus and pemphigus vulgaris [<a href="#rid78">78-81</a>], and pemphigus has been reported to develop following burns or cutaneous electrical injury [<a href="#rid82">82</a>]. Viral infections, certain food compounds, ionizing radiation, and pesticides have been suggested as additional stimuli for this disease [<a href="#rid83">83-88</a>].</p><p class="headingAnchor" id="H118261971"><span class="h3">Drug exposure</span><span class="headingEndMark"> — </span>Pemphigus vulgaris and pemphigus foliaceus may be precipitated by drugs. Thiol drugs, including <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a> and <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a>, are the most common inciting agents [<a href="#rid89">89</a>]. In one series of 104 patients treated with penicillamine for at least six months, 7 percent developed pemphigus foliaceus [<a href="#rid90">90</a>]. Examples of additional drugs that have been associated with pemphigus vulgaris or pemphigus foliaceus include penicillins, cephalosporins, <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and nonsteroidal anti-inflammatory agents  (<a class="graphic graphic_table graphicRef88293" href="/z/d/graphic/88293.html" rel="external">table 2</a>) [<a href="#rid89">89,91,92</a>].</p><p>Drug-induced biochemical and/or immunologic reactions may contribute to the development of acantholysis in drug-induced pemphigus. Potential mechanisms include effects on enzymes that mediate keratinocyte aggregation, direct interference through binding to molecules involved in cell adhesion, and stimulation of neoantigen formation [<a href="#rid91">91</a>].</p><p>Direct immunofluorescence (DIF) and indirect immunofluorescence (IIF) studies are negative in some patients with drug-induced pemphigus. In a series of six patients with this disorder, DIF was negative in one patient and IIF was negative in two patients [<a href="#rid92">92</a>]. ELISA was positive for desmoglein 1 or desmoglein 3 in all patients in this series.</p><p>The introduction of immune checkpoint inhibitors in the treatment of various solid tumors has revealed novel, immune-related adverse events, including loss of self-tolerance and the development of autoimmunity. In addition to the induction of lichenoid dermatitis, bullous pemphigoid, and granulomatous/sarcoid-like reactions, there are several cases of pemphigus vulgaris, pemphigus foliaceus, or paraneoplastic pemphigus that developed de novo or found to be aggravated upon introduction of the immune checkpoint inhibitor [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H137385107"><span class="h3">Diet</span><span class="headingEndMark"> — </span>Dietary factors including garlic, leek, onion, black pepper, red chili pepper, red wine, and tea have been implicated as inducers of pemphigus vulgaris and pemphigus foliaceus based on concise case reports. However, the existing evidence does not support a strong link between diet as an environmental factor and pemphigus [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H181679718"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H181679726"><span class="h2">Pemphigus vulgaris</span><span class="headingEndMark"> — </span>Almost all patients with pemphigus vulgaris develop mucosal involvement. The oral cavity is the most common site of mucosal lesions and often represents the initial site of disease [<a href="#rid94">94</a>]. Mucous membranes at other sites are also often affected, including the conjunctiva, nose, esophagus, vulva, vagina, cervix, and anus [<a href="#rid95">95-97</a>]. In women with cervical involvement, the histologic findings of pemphigus vulgaris may be mistaken for cervical dysplasia in Papanicolaou (Pap) smears [<a href="#rid98">98</a>].</p><p>Since mucosal blisters erode quickly, erosions are often the only clinical findings  (<a class="graphic graphic_picture graphicRef57924 graphicRef77462 graphicRef56333" href="/z/d/graphic/57924.html" rel="external">picture 2A-C</a>). The buccal mucosa and palatine mucosa are the most common sites for lesion development in the oral cavity [<a href="#rid99">99</a>].</p><p>The pain associated with mucosal involvement of pemphigus vulgaris can be severe. Oral pain is often augmented by chewing and swallowing, which may result in poor alimentation, weight loss, and malnutrition.</p><p>Most patients also develop cutaneous involvement manifesting as flaccid blisters on normal-appearing or erythematous skin  (<a class="graphic graphic_picture graphicRef53425 graphicRef51868" href="/z/d/graphic/53425.html" rel="external">picture 3A-B</a>). The blisters rupture easily, resulting in painful erosions that bleed easily  (<a class="graphic graphic_picture graphicRef51868 graphicRef63170 graphicRef74842" href="/z/d/graphic/51868.html" rel="external">picture 3B-D</a>). Pruritus usually is absent. Although any cutaneous site may be affected, the palms and soles are usually spared. The <strong>Nikolsky sign</strong> (induction of blistering via mechanical pressure at the edge of a blister or on normal skin) often can be elicited [<a href="#rid100">100</a>]. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Nikolsky sign'</a>.)</p><p>Rarely, mucous membrane involvement is not observed despite the presence of circulating autoantibodies to both desmoglein 1 and desmoglein 3 [<a href="#rid101">101-103</a>]. The term "cutaneous-type pemphigus vulgaris" is used to refer to this presentation of the disease. (See <a class="local">'Target antigens'</a> above.)</p><p>Other uncommon clinical presentations of pemphigus vulgaris include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus vegetans</strong> – Patients with pemphigus vegetans present with vegetating plaques composed of excessive granulation tissue and crusting  (<a class="graphic graphic_picture graphicRef60187" href="/z/d/graphic/60187.html" rel="external">picture 4</a>). The intertriginous areas, scalp, and face are the most common sites for these lesions. Two clinical presentations of pemphigus vegetans have been described [<a href="#rid104">104</a>]. In <strong>pemphigus vegetans of Neumann</strong>, vegetating plaques evolve from typical pemphigus vulgaris lesions. <strong>Pemphigus vegetans of Hallopeau</strong> is a milder form of pemphigus vegetans in which the vegetating plaques are not preceded by bullae. Lesions of pemphigus vegetans of Hallopeau usually are found in intertriginous areas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus herpetiformis </strong>–<strong> </strong>Pemphigus herpetiformis (also known as herpetiform pemphigus) is a term that describes pemphigus vulgaris or pemphigus foliaceus that manifests with urticarial plaques and cutaneous vesicles arranged in a herpetiform or annular pattern  (<a class="graphic graphic_picture graphicRef87495" href="/z/d/graphic/87495.html" rel="external">picture 5</a>) [<a href="#rid1">1,105-108</a>]. Pruritus is frequently present. Mucosal involvement is uncommon.</p><p></p><p>The clinical features of drug-induced pemphigus vulgaris are similar to idiopathic disease.</p><p class="headingAnchor" id="H181679733"><span class="h2">Pemphigus foliaceus</span><span class="headingEndMark"> — </span>Pemphigus foliaceus is a superficial variant of pemphigus that presents with cutaneous lesions. The mucous membranes are typically spared [<a href="#rid1">1</a>].</p><p>Pemphigus foliaceus usually develops in a seborrheic distribution. The scalp, face, and trunk are common sites of involvement. The skin lesions usually consist of small, scattered superficial blisters that rapidly evolve into scaly, crusted erosions  (<a class="graphic graphic_picture graphicRef54341 graphicRef60530 graphicRef72419" href="/z/d/graphic/54341.html" rel="external">picture 6A-C</a>). The Nikolsky sign often is present [<a href="#rid13">13</a>]. The skin lesions may remain localized or may coalesce to cover large areas of skin. Occasionally, pemphigus foliaceus progresses to involve the entire skin surface as an exfoliative erythroderma [<a href="#rid12">12</a>].</p><p>Pain or burning sensations frequently accompany the cutaneous lesions. Systemic symptoms are usually absent.</p><p>Clinical variants of pemphigus foliaceus include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endemic pemphigus foliaceus (fogo selvagem) </strong>–<strong> </strong>Endemic pemphigus foliaceus presents with clinical features that are similar to the idiopathic form of the disease [<a href="#rid13">13</a>]. An environmental trigger is believed to account for this variant of the disease. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus erythematosus (Senear-Usher syndrome)</strong> – This term pemphigus erythematosus is used to describe pemphigus foliaceus localized to the malar region of the face  (<a class="graphic graphic_picture graphicRef87180" href="/z/d/graphic/87180.html" rel="external">picture 7</a>) [<a href="#rid12">12</a>]. Historically, the term was used to refer to patients who exhibited immunofluorescence findings consistent with pemphigus as well as laboratory features of systemic lupus erythematosus. However, the term is no longer used in this manner.</p><p></p><p>The clinical manifestations of drug-induced pemphigus foliaceus are similar to idiopathic disease.</p><p class="headingAnchor" id="H181679747"><span class="h2">IgA pemphigus</span><span class="headingEndMark"> — </span>Both the subcorneal pustular dermatosis and intraepidermal neutrophilic IgA dermatosis types of IgA pemphigus are characterized by the subacute development of vesicles that evolve into pustules [<a href="#rid6">6</a>]. The vesicles and pustules are usually, but not always, accompanied by erythematous plaques. A herpetiform, annular, or circinate pattern may be present [<a href="#rid6">6,57,99</a>].</p><p>The trunk and proximal extremities are common sites for involvement. The scalp, postauricular skin, and intertriginous areas are less common sites for lesion development [<a href="#rid6">6,57,109</a>]. Pruritus may or may not be present. Mucous membranes are usually spared.</p><p>The subcorneal pustular dermatosis type of IgA pemphigus is clinically similar to classic subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Immunofluorescence studies are necessary to distinguish these diseases. (See  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses", section on 'Subcorneal pustular dermatosis'</a> and <a class="local">'IgA pemphigus'</a> below.)</p><p class="headingAnchor" id="H20091728"><span class="h2">Paraneoplastic pemphigus</span><span class="headingEndMark"> — </span>Paraneoplastic pemphigus (also known as paraneoplastic autoimmune multiorgan syndrome) is an autoimmune multi-organ syndrome associated with neoplastic disease [<a href="#rid27">27</a>]. Typically, patients suffer from severe and acute mucosal involvement with extensive, intractable stomatitis  (<a class="graphic graphic_picture graphicRef59594 graphicRef79518 graphicRef54382" href="/z/d/graphic/59594.html" rel="external">picture 8A-C</a>). The cutaneous manifestations are variable, and include blisters, erosions, and lichenoid lesions that may resemble other autoimmune blistering diseases, erythema multiforme, graft versus host disease, or lichen planus  (<a class="graphic graphic_picture graphicRef67265 graphicRef79192" href="/z/d/graphic/67265.html" rel="external">picture 9A-B</a>). Life-threatening pulmonary involvement consistent with bronchiolitis obliterans also may be seen [<a href="#rid110">110</a>]. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H1054869"><span class="h2">Neonatal pemphigus</span><span class="headingEndMark"> — </span>Neonatal pemphigus is a rare transient condition in which neonates develop blisters due to placental transmission of autoantibodies from a mother with pemphigus. Neonatal pemphigus vulgaris occurs more frequently than neonatal pemphigus foliaceus [<a href="#rid111">111,112</a>]. The clinical, histologic, and direct immunofluorescence findings of neonatal pemphigus are consistent with pemphigus. Indirect immunofluorescence has been positive in the majority of reported cases [<a href="#rid111">111</a>]. The disease manifestations usually resolve within three weeks.</p><p class="headingAnchor" id="H2330474617"><span class="h1">COMORBIDITIES</span><span class="headingEndMark"> — </span>Cross-sectional studies have found increased prevalence rates for other disorders in patients with pemphigus, including hematologic malignancies, solid malignancies (esophageal and laryngeal cancer), other autoimmune diseases (Sjögren's disease, systemic lupus erythematosus, and alopecia areata), psoriasis, and neurologic diseases (dementia, Parkinson disease, and epilepsy) [<a href="#rid113">113-116</a>]. Further studies are necessary to firmly establish the clinical relevance of these findings. </p><p>Although an increased prevalence of malignancy in patients with pemphigus has been reported, malignancy is uncommon overall [<a href="#rid113">113,117</a>]. A cross-sectional study of 1985 patients with pemphigus vulgaris or pemphigus foliaceus and 9874 matched controls found modest increases in the prevalence rates of chronic leukemia (0.9 versus 0.4 percent, odds ratio [OR] 2.1, 95% CI 1.2-3.6), multiple myeloma (0.8 versus 0.4 percent, OR 2.2, 95% CI 1.2-3.9), and non-Hodgkin lymphoma (1.8 versus 1.2 percent, OR 1.5, 95% CI 1.0-2.2) among pemphigus patients [<a href="#rid117">117</a>]. Paraneoplastic pemphigus, a very rare obligate paraneoplastic disease, is a distinct subtype of pemphigus that occurs only in association with malignancy and is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p class="headingAnchor" id="H458196"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of pemphigus is made through the assessment of clinical, histologic, immunopathologic, and serologic findings  (<a class="graphic graphic_table graphicRef87920" href="/z/d/graphic/87920.html" rel="external">table 1</a>). Even in cases in which the clinical findings strongly suggest pemphigus, laboratory investigations to confirm the diagnosis are indicated since other disorders may present with similar clinical findings. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H176631212"><span class="h2">Pemphigus vulgaris and pemphigus foliaceus</span><span class="headingEndMark"> — </span>In addition to a complete examination of cutaneous and mucosal surfaces, the clinical assessment should include a review of the patient's medications since clinical and laboratory studies cannot reliably distinguish between idiopathic pemphigus and drug-induced pemphigus. In addition, patients who may have pemphigus vulgaris should be questioned about ocular symptoms, hoarseness, dysphagia, dysuria, and dyspareunia to evaluate for symptoms suggestive of extraoral mucus membrane involvement. (See <a class="local">'Drug exposure'</a> above and <a class="local">'Clinical features'</a> above.)</p><p>Our standard laboratory work-up for patients with clinical findings suggestive of pemphigus vulgaris or foliaceus includes:</p><p class="bulletIndent1"><span class="glyph">●</span>A <strong>lesional </strong>skin or mucosal biopsy for routine hematoxylin and eosin (H&amp;E) staining</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A <strong>perilesional</strong> skin or mucosal biopsy for direct immunofluorescence (DIF)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum collection for enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (IIF)</p><p></p><p class="headingAnchor" id="H176631221"><span class="h3">Histopathology</span><span class="headingEndMark"> — </span>The biopsy for routine histologic examination should be taken from an early lesion. The biopsy should be placed at the edge of a blister or erosion. A 4 mm punch biopsy is usually sufficient. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Skin biopsy'</a>.)</p><p>The characteristic findings in <strong>pemphigus vulgaris</strong> include  (<a class="graphic graphic_picture graphicRef117153" href="/z/d/graphic/117153.html" rel="external">picture 10</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Intraepithelial cleavage with acantholysis (detached keratinocytes) primarily localized to the suprabasal region</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retention of basal keratinocytes along the basement membrane zone, resulting in an appearance that resembles a "row of tombstones"</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sparse inflammatory infiltrate in the dermis with eosinophils</p><p></p><p>In the pemphigus vegetans variant of pemphigus vulgaris, the suprabasal cleavage is accompanied by hyperkeratosis, papillomatosis, and prominent acanthosis with downward proliferation of the rete ridges [<a href="#rid118">118</a>]. Eosinophils may be present within the areas of cleavage.</p><p>The characteristic findings of <strong>pemphigus foliaceus</strong> include  (<a class="graphic graphic_picture graphicRef57313" href="/z/d/graphic/57313.html" rel="external">picture 11</a>) [<a href="#rid118">118</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intraepithelial cleavage with acantholysis beneath the stratum corneum or within the granular layer; neutrophils within the blister cavity are occasionally seen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed inflammatory infiltrate in the superficial dermis with eosinophils and neutrophils; eosinophils may be more prevalent in drug-induced pemphigus foliaceus</p><p></p><p class="headingAnchor" id="H176631240"><span class="h3">Direct immunofluorescence</span><span class="headingEndMark"> — </span>Unlike the biopsy for routine histologic examination, the biopsy for DIF should be taken from normal-appearing perilesional skin or mucosa. The biopsy should <strong>not </strong>be placed in formalin. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Direct immunofluorescence'</a>.)</p><p>Both pemphigus vulgaris and pemphigus foliaceus demonstrate intercellular deposition of IgG on DIF  (<a class="graphic graphic_picture graphicRef82837 graphicRef82838" href="/z/d/graphic/82837.html" rel="external">picture 1A-B</a>). Although some cases of pemphigus foliaceus demonstrate deposition of IgG that is primarily distributed in upper levels of the epidermis  (<a class="graphic graphic_picture graphicRef82838" href="/z/d/graphic/82838.html" rel="external">picture 1B</a>), DIF cannot be used to reliably distinguish between these diseases.</p><p>Essentially all patients with idiopathic pemphigus vulgaris or pemphigus foliaceus have positive DIF results. Thus, if DIF is negative, the diagnosis should be questioned. In contrast, negative DIF studies may occur in patients with drug-induced pemphigus (see <a class="local">'Drug exposure'</a> above) [<a href="#rid89">89,92</a>]. Occasionally, intercellular deposition of antibodies occurs in other diseases (eg, spongiotic dermatitis, burns, toxic epidermal necrolysis, systemic lupus erythematosus, or lichen planus) [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H176631249"><span class="h3">Serology</span><span class="headingEndMark"> — </span>IIF and ELISA are serologic studies that can detect circulating autoantibodies that bind epithelial cell surface antigens. In patients with positive DIF results, these tests are used to further support the diagnosis of pemphigus.</p><p class="headingAnchor" id="H176631269"><span class="h4">Indirect immunofluorescence</span><span class="headingEndMark"> — </span>More than 80 percent of patients with pemphigus vulgaris or pemphigus foliaceus have circulating antibodies detectable by IIF [<a href="#rid104">104</a>]. The substrate used influences the test sensitivity [<a href="#rid104">104</a>]. Monkey esophagus is the preferred substrate for the diagnosis of pemphigus vulgaris. In contrast, normal human skin and guinea pig esophagus are the most sensitive substrates for the diagnosis of pemphigus foliaceus. In both disorders, IgG deposits are found intercellularly  (<a class="graphic graphic_picture graphicRef82839" href="/z/d/graphic/82839.html" rel="external">picture 12</a>). IIF cannot be used to distinguish between these diseases. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Indirect immunofluorescence'</a>.)</p><p class="headingAnchor" id="H176631299"><span class="h4">Enzyme-linked immunosorbent assay</span><span class="headingEndMark"> — </span>ELISA for IgG antibodies to desmoglein 1 and desmoglein 3 is commercially available. ELISA is more sensitive and specific than IIF for the diagnosis of pemphigus vulgaris and pemphigus foliaceus [<a href="#rid104">104</a>]. The sensitivity of ELISA exceeds 90 percent [<a href="#rid12">12</a>].</p><p>In addition, since desmoglein antibody levels often fall in the setting of clinical improvement, ELISA may aid with monitoring disease activity and the response to treatment [<a href="#rid119">119-121</a>]. In a retrospective study that assessed the predictive values of pemphigus autoantibodies in patients with pemphigus vulgaris and pemphigus foliaceus, desmoglein 1 autoantibodies were more closely correlated with the disease course than desmoglein 3 autoantibodies [<a href="#rid120">120</a>]. Desmoglein 3 antibody levels remained high during disease remissions in some patients with mucosal pemphigus vulgaris. In patients with pemphigus vulgaris, levels of IgE antibodies to desmoglein 3 may also correlate with disease activity [<a href="#rid122">122</a>]. (See  <a class="medical medical_review" href="/z/d/html/15303.html" rel="external">"Initial management of pemphigus vulgaris and pemphigus foliaceus"</a> and  <a class="medical medical_review" href="/z/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p class="headingAnchor" id="H176631615"><span class="h4">Other</span><span class="headingEndMark"> — </span>Additional serologic tests that may be used for the diagnosis of pemphigus vulgaris and pemphigus foliaceus include immunoblotting and immunoprecipitation. However, these tests are more difficult to perform than IIF and ELISA. Thus, they are infrequently used in the clinical setting.</p><p>Aside from the detection of pemphigus antibodies in serum, pemphigus is not associated with specific laboratory abnormalities. Other laboratory abnormalities may occur related to complications of the disease or its treatment. </p><p class="headingAnchor" id="H176631509"><span class="h2">IgA pemphigus</span><span class="headingEndMark"> — </span>Similar to other forms of pemphigus, the diagnosis of IgA pemphigus is based upon the combined assessment of clinical and laboratory findings. The standard laboratory workup consists of histologic examination, DIF, and IIF.</p><p>Typical histologic findings of IgA pemphigus include [<a href="#rid6">6,118</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intraepidermal clefts and pustules located in a subcorneal location (subcorneal pustular dermatosis-type IgA pemphigus) or in the entire or mid-epidermis (intraepithelial neutrophilic dermatosis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Slight or absent acantholysis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed inflammatory infiltrate in the dermis</p><p></p><p>DIF microscopy of perilesional skin reveals intercellular IgA deposition within the epidermis that is occasionally more pronounced in the upper epidermis. Weaker intercellular deposits of IgG and/or C3 may also be present [<a href="#rid6">6,57</a>]. IIF on monkey esophagus demonstrating intercellular deposits of IgA offers further support for the diagnosis. However, IIF on monkey esophagus is positive in less than or equal to 50 percent of patients [<a href="#rid6">6,57</a>]. IIF on human skin may demonstrate intercellular antibody deposition more frequently; in one series of patients with IgA pemphigus, IIF of normal human skin showed intercellular deposition of IgA in 31 of 48 patients (65 percent) [<a href="#rid57">57</a>].</p><p>Other studies that have been utilized to identify circulating IgA pemphigus desmocollin autoantibodies include immunoblotting [<a href="#rid123">123</a>], ELISA using recombinant desmocollin [<a href="#rid57">57,109</a>], and immunofluorescence molecular assay using desmocollin-transfected COS-7 cells [<a href="#rid55">55,57</a>]. The availability of these studies is limited to specialized centers and research settings.</p><p>Although autoantibodies against desmocollin 1 appear to be strongly associated with the subcorneal pustular dermatosis type of IgA pemphigus, autoantibodies to desmogleins may be present in other patients with IgA pemphigus [<a href="#rid56">56,57</a>]. In one series of 22 patients with IgA pemphigus, ELISA tests for IgA autoantibodies against desmoglein 1 or desmoglein 3 were positive in three patients and one patient, respectively [<a href="#rid56">56</a>]. The patients with desmoglein autoantibodies had either the intraepidermal neutrophilic type of IgA pemphigus or a presentation that had clinical and pathologic features of pemphigus foliaceus. None of the 10 patients with subcorneal pustular dermatosis-type IgA pemphigus had autoantibodies against these desmogleins, but all 10 had serum samples that reacted with desmocollin 1 expressing COS-7 cells.</p><p class="headingAnchor" id="H1056011"><span class="h2">Paraneoplastic pemphigus</span><span class="headingEndMark"> — </span>Similar to other forms of pemphigus, the diagnosis of paraneoplastic pemphigus involves review of clinical, histologic, immunopathologic, and serologic findings. The diagnosis of paraneoplastic pemphigus vulgaris is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H259760408"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Multiple mucocutaneous blistering diseases share clinical features with the different forms of pemphigus  (<a class="graphic graphic_table graphicRef60255" href="/z/d/graphic/60255.html" rel="external">table 3</a>). In all forms of pemphigus, laboratory investigations, particularly immunopathologic tests, usually easily distinguish pemphigus from other diseases:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus vulgaris </strong>– Cutaneous involvement in pemphigus vulgaris must be distinguished from other autoimmune blistering diseases. The morphology of cutaneous blisters in pemphigus vulgaris can be helpful for narrowing the differential diagnosis. The flaccid blisters often seen in pemphigus vulgaris contrast with the tense blisters that are frequently seen in association with subepithelial blistering diseases, such as bullous pemphigoid, linear IgA bullous dermatosis, and epidermolysis bullosa acquisita  (<a class="graphic graphic_picture graphicRef70352 graphicRef56434 graphicRef62505" href="/z/d/graphic/70352.html" rel="external">picture 13A-C</a> and <a class="graphic graphic_algorithm graphicRef103314" href="/z/d/graphic/103314.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a> and  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Clinical features of bullous pemphigoid'</a> and  <a class="medical medical_review" href="/z/d/html/15301.html" rel="external">"Linear IgA bullous dermatosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/15299.html" rel="external">"Epidermolysis bullosa acquisita", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Mucosal lesions pemphigus vulgaris can resemble other blistering or erosive disorders of the mucous membranes. As examples, the possibility of other pemphigus variants, mucous membrane pemphigoid, mucosal linear IgA bullous dermatosis or epidermolysis bullosa acquisita, erythema multiforme, and Stevens-Johnson syndrome should be considered. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Mucous membrane involvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigus foliaceus </strong>– The lesions of pemphigus foliaceus may resemble other inflammatory disorders, such as seborrheic dermatitis  (<a class="graphic graphic_picture graphicRef76985" href="/z/d/graphic/76985.html" rel="external">picture 14</a>), impetigo, subacute cutaneous lupus erythematosus  (<a class="graphic graphic_picture graphicRef55903 graphicRef66580" href="/z/d/graphic/55903.html" rel="external">picture 15A-B</a>), IgA pemphigus, and the non-IgA pemphigus form of subcorneal pustular dermatosis  (<a class="graphic graphic_picture graphicRef52552 graphicRef71995" href="/z/d/graphic/52552.html" rel="external">picture 16A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses", section on 'Subcorneal pustular dermatosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgA pemphigus </strong>– The differential diagnosis of IgA pemphigus overlaps with pemphigus foliaceus. In addition, disorders that may present with grouped vesicular lesions or pustules, such as dermatitis herpetiformis  (<a class="graphic graphic_picture graphicRef86768" href="/z/d/graphic/86768.html" rel="external">picture 17</a>), bullous impetigo, linear IgA bullous dermatosis  (<a class="graphic graphic_picture graphicRef56434" href="/z/d/graphic/56434.html" rel="external">picture 13B</a>), and pustular psoriasis  (<a class="graphic graphic_picture graphicRef56926 graphicRef67402" href="/z/d/graphic/56926.html" rel="external">picture 18A-B</a>) should be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic pemphigus </strong>– The differential diagnosis of paraneoplastic pemphigus is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus", section on 'Differential diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H950509241"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/132082.html" rel="external">"Society guideline links: Pemphigus"</a>.)</p><p class="headingAnchor" id="H259760420"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Pemphigus comprises a group of autoimmune blistering diseases that are characterized by histologic acantholysis (loss of cell-to-cell adhesion) and mucosal and/or cutaneous blistering. The four major types of pemphigus are pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, and paraneoplastic pemphigus  (<a class="graphic graphic_table graphicRef87920" href="/z/d/graphic/87920.html" rel="external">table 1</a>). (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Pemphigus is rare. Pemphigus vulgaris is the most common form of pemphigus. However, in certain areas, particularly in locations where an endemic form of pemphigus foliaceus occurs, pemphigus foliaceus is more prevalent. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The intraepidermal blistering observed in pemphigus occurs due to an immune response that results in the deposition of autoantibodies against epidermal cell surface antigens within the epithelium of mucous membranes or skin  (<a class="graphic graphic_figure graphicRef87356" href="/z/d/graphic/87356.html" rel="external">figure 2</a>). The mechanism through which acantholysis occurs is not fully understood. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Pemphigus vulgaris generally is a more severe disease than pemphigus foliaceus. Patients with pemphigus vulgaris usually present with widespread mucocutaneous blisters and erosions  (<a class="graphic graphic_picture graphicRef57924 graphicRef77462 graphicRef53425 graphicRef51868 graphicRef63170 graphicRef74842" href="/z/d/graphic/57924.html" rel="external">picture 2A-B, 3A-D</a>). Cutaneous blistering in pemphigus foliaceus tends to occur in a seborrheic distribution  (<a class="graphic graphic_picture graphicRef54341 graphicRef60530 graphicRef72419" href="/z/d/graphic/54341.html" rel="external">picture 6A-C</a>). Compared with pemphigus vulgaris, blistering in pemphigus foliaceus is more superficial. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">Vesicles, pustules, and crusts on skin are common features of IgA pemphigus. The skin lesions may appear in an annular, circinate, or herpetiform distribution. (See <a class="local">'IgA pemphigus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of pemphigus is based upon the recognition of consistent clinical, histologic, and direct immunofluorescence (DIF) findings, as well as the detection of circulating IgG and IgA autoantibodies against cell surface antigens in serum  (<a class="graphic graphic_table graphicRef87920" href="/z/d/graphic/87920.html" rel="external">table 1</a>). Laboratory studies are useful for distinguishing pemphigus from other blistering and erosive diseases. Our standard laboratory work-up for patients with clinical findings suggestive of pemphigus vulgaris or foliaceus includes (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A <strong>lesional </strong>skin or mucosal biopsy for routine hematoxylin and eosin (H&amp;E) staining</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A <strong>perilesional</strong> skin or mucosal biopsy for DIF</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum collection for detection of autoantibodies by enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (IIF)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007; 11:462.</a></li><li><a class="nounderline abstract_t">Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol 2005; 14:861.</a></li><li><a class="nounderline abstract_t">Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006; 116:1159.</a></li><li><a class="nounderline abstract_t">Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers 2017; 3:17026.</a></li><li><a class="nounderline abstract_t">Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol 2019; 10:1418.</a></li><li><a class="nounderline abstract_t">Tsuruta D, Ishii N, Hamada T, et al. IgA pemphigus. Clin Dermatol 2011; 29:437.</a></li><li><a class="nounderline abstract_t">Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9:844.</a></li><li><a class="nounderline abstract_t">Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res 2018; 66:255.</a></li><li><a class="nounderline abstract_t">Meyer N, Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010; 9:A379.</a></li><li><a class="nounderline abstract_t">Hans-Filho G, dos Santos V, Katayama JH, et al. An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research. J Invest Dermatol 1996; 107:68.</a></li><li><a class="nounderline abstract_t">Rocha-Alvarez R, Ortega-Loayza AG, Friedman H, et al. Endemic pemphigus vulgaris. Arch Dermatol 2007; 143:895.</a></li><li><a class="nounderline abstract_t">Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol 2011; 29:432.</a></li><li><a class="nounderline abstract_t">James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin 2011; 29:405.</a></li><li><a class="nounderline abstract_t">Diaz LA, Sampaio SA, Rivitti EA, et al. Endemic pemphigus foliaceus (Fogo Selvagem): II. Current and historic epidemiologic studies. J Invest Dermatol 1989; 92:4.</a></li><li><a class="nounderline abstract_t">Brenner S, Wohl Y. A survey of sex differences in 249 pemphigus patients and possible explanations. Skinmed 2007; 6:163.</a></li><li><a class="nounderline abstract_t">Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol 1995; 104:302.</a></li><li><a class="nounderline abstract_t">Abrèu-Velez AM, Hashimoto T, Bollag WB, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol 2003; 49:599.</a></li><li><a class="nounderline abstract_t">Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006; 355:1800.</a></li><li><a class="nounderline abstract_t">Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clin Rev Allergy Immunol 2018; 54:1.</a></li><li><a class="nounderline abstract_t">Hu CH, Michel B, Schiltz JR. Epidermal acantholysis induced in vitro by pemphigus autoantibody. An ultrastructural study. Am J Pathol 1978; 90:345.</a></li><li><a class="nounderline abstract_t">Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 1976; 67:254.</a></li><li><a class="nounderline abstract_t">Schiltz JR, Michel B, Papay R. Pemphigus antibody interaction with human epidermal cells in culture. J Clin Invest 1978; 62:778.</a></li><li><a class="nounderline abstract_t">Supapannachart N, Mutasim DF. The distribution of IgA pemphigus antigen in human skin and the role of IgA anti-cell surface antibodies in the induction of intraepidermal acantholysis. Arch Dermatol 1993; 129:605.</a></li><li><a class="nounderline abstract_t">Anhalt GJ, Labib RS, Voorhees JJ, et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306:1189.</a></li><li><a class="nounderline abstract_t">Ding X, Diaz LA, Fairley JA, et al. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol 1999; 112:739.</a></li><li><a class="nounderline abstract_t">Roscoe JT, Diaz L, Sampaio SA, et al. Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol 1985; 85:538.</a></li><li><a class="nounderline abstract_t">Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323:1729.</a></li><li><a class="nounderline abstract_t">Futamura S, Martins C, Rivitti EA, et al. Ultrastructural studies of acantholysis induced in vivo by passive transfer of IgG from endemic pemphigus foliaceus (Fogo Selvagem). J Invest Dermatol 1989; 93:480.</a></li><li><a class="nounderline abstract_t">Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94:59.</a></li><li><a class="nounderline abstract_t">Amagai M, Hashimoto T, Green KJ, et al. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995; 104:895.</a></li><li><a class="nounderline abstract_t">Waschke J. The desmosome and pemphigus. Histochem Cell Biol 2008; 130:21.</a></li><li><a class="nounderline abstract_t">Getsios S, Waschke J, Borradori L, et al. From cell signaling to novel therapeutic concepts: international pemphigus meeting on advances in pemphigus research and therapy. J Invest Dermatol 2010; 130:1764.</a></li><li><a class="nounderline abstract_t">Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity 2012; 45:7.</a></li><li><a class="nounderline abstract_t">Amagai M, Tsunoda K, Zillikens D, et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40:167.</a></li><li><a class="nounderline abstract_t">Ding X, Aoki V, Mascaro JM Jr, et al. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109:592.</a></li><li><a class="nounderline abstract_t">Amagai M, Karpati S, Prussick R, et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992; 90:919.</a></li><li><a class="nounderline abstract_t">Bhol K, Natarajan K, Nagarwalla N, et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A 1995; 92:5239.</a></li><li><a class="nounderline abstract_t">Hudemann C, Maglie R, Llamazares-Prada M, et al. Human Desmocollin 3‒Specific IgG Antibodies Are Pathogenic in a Humanized HLA Class II Transgenic Mouse Model of Pemphigus. J Invest Dermatol 2022; 142:915.</a></li><li><a class="nounderline abstract_t">Rock B, Martins CR, Theofilopoulos AN, et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989; 320:1463.</a></li><li><a class="nounderline abstract_t">Funakoshi T, Lunardon L, Ellebrecht CT, et al. Enrichment of total serum IgG4 in patients with pemphigus. Br J Dermatol 2012; 167:1245.</a></li><li><a class="nounderline abstract_t">Golinski ML, Lemieux A, Maho-Vaillant M, et al. The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab. Front Immunol 2022; 13:849790.</a></li><li><a class="nounderline abstract_t">Mahoney MG, Wang Z, Rothenberger K, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999; 103:461.</a></li><li><a class="nounderline abstract_t">Sardana K, Garg VK, Agarwal P. Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms? Br J Dermatol 2013; 168:669.</a></li><li><a class="nounderline abstract_t">Jamora MJ, Jiao D, Bystryn JC. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. J Am Acad Dermatol 2003; 48:976.</a></li><li><a class="nounderline abstract_t">Mao X, Nagler AR, Farber SA, et al. Autoimmunity to desmocollin 3 in pemphigus vulgaris. Am J Pathol 2010; 177:2724.</a></li><li><a class="nounderline abstract_t">Rafei D, Müller R, Ishii N, et al. IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. Am J Pathol 2011; 178:718.</a></li><li><a class="nounderline abstract_t">Müller R, Heber B, Hashimoto T, et al. Autoantibodies against desmocollins in European patients with pemphigus. Clin Exp Dermatol 2009; 34:898.</a></li><li><a class="nounderline abstract_t">Tateishi C, Tsuruta D, Nakanishi T, et al. Antidesmocollin-1 antibody-positive, antidesmoglein antibody-negative pemphigus herpetiformis. J Am Acad Dermatol 2010; 63:e8.</a></li><li><a class="nounderline abstract_t">Kljuic A, Bazzi H, Sundberg JP, et al. Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris. Cell 2003; 113:249.</a></li><li><a class="nounderline abstract_t">Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000; 275:29466.</a></li><li><a class="nounderline abstract_t">Nguyen VT, Ndoye A, Grando SA. Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol 2000; 157:1377.</a></li><li><a class="nounderline abstract_t">Nguyen VT, Ndoye A, Shultz LD, et al. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000; 106:1467.</a></li><li><a class="nounderline abstract_t">Nagasaka T, Nishifuji K, Ota T, et al. Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome. J Clin Invest 2004; 114:1484.</a></li><li><a class="nounderline abstract_t">Hashimoto T. Immunopathology of IgA pemphigus. Clin Dermatol 2001; 19:683.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Kiyokawa C, Mori O, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol 1997; 109:127.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Komai A, Futei Y, et al. Detection of IgA autoantibodies to desmogleins by an enzyme-linked immunosorbent assay: the presence of new minor subtypes of IgA pemphigus. Arch Dermatol 2001; 137:735.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Teye K, Ishii N. Clinical and immunological studies of 49 cases of various types of intercellular IgA dermatosis and 13 cases of classical subcorneal pustular dermatosis examined at Kurume University. Br J Dermatol 2017; 176:168.</a></li><li><a class="nounderline abstract_t">Prost C, Intrator L, Wechsler J, et al. IgA autoantibodies bind to pemphigus vulgaris antigen in a case of intraepidermal neutrophilic IgA dermatosis. J Am Acad Dermatol 1991; 25:846.</a></li><li><a class="nounderline abstract_t">Wang J, Kwon J, Ding X, et al. Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis. Am J Pathol 1997; 150:1901.</a></li><li><a class="nounderline abstract_t">Kárpáti S, Amagai M, Liu WL, et al. Identification of desmoglein 1 as autoantigen in a patient with intraepidermal neutrophilic IgA dermatosis type of IgA pemphigus. Exp Dermatol 2000; 9:224.</a></li><li><a class="nounderline abstract_t">Ishii N, Ishida-Yamamoto A, Hashimoto T. Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol 2004; 29:62.</a></li><li><a class="nounderline abstract_t">Firooz A, Mazhar A, Ahmed AR. Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris. J Am Acad Dermatol 1994; 31:434.</a></li><li><a class="nounderline abstract_t">Abida O, Kallel-Sellami M, Joly P, et al. Anti-desmoglein 1 antibodies in healthy related and unrelated subjects and patients with pemphigus foliaceus in endemic and non-endemic areas from Tunisia. J Eur Acad Dermatol Venereol 2009; 23:1073.</a></li><li><a class="nounderline abstract_t">Brautbar C, Moscovitz M, Livshits T, et al. HLA-DRw4 in pemphigus vulgaris patients in Israel. Tissue Antigens 1980; 16:238.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Wagner R, Khatri K, et al. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci U S A 1991; 88:5056.</a></li><li><a class="nounderline abstract_t">Szafer F, Brautbar C, Tzfoni E, et al. Detection of disease-specific restriction fragment length polymorphisms in pemphigus vulgaris linked to the DQw1 and DQw3 alleles of the HLA-D region. Proc Natl Acad Sci U S A 1987; 84:6542.</a></li><li><a class="nounderline abstract_t">Sinha AA, Brautbar C, Szafer F, et al. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 1988; 239:1026.</a></li><li><a class="nounderline abstract_t">Miyagawa S, Higashimine I, Iida T, et al. HLA-DRB1*04 and DRB1*14 alleles are associated with susceptibility to pemphigus among Japanese. J Invest Dermatol 1997; 109:615.</a></li><li><a class="nounderline abstract_t">Lombardi ML, Mercuro O, Ruocco V, et al. Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. J Invest Dermatol 1999; 113:107.</a></li><li><a class="nounderline abstract_t">Petzl-Erler ML, Santamaria J. Are HLA class II genes controlling susceptibility and resistance to Brazilian pemphigus foliaceus (fogo selvagem)? Tissue Antigens 1989; 33:408.</a></li><li><a class="nounderline abstract_t">Cerna M, Fernandez-Viña M, Friedman H, et al. Genetic markers for susceptibility to endemic Brazilian pemphigus foliaceus (Fogo Selvagem) in Xavante Indians. Tissue Antigens 1993; 42:138.</a></li><li><a class="nounderline abstract_t">Abida O, Zitouni M, Kallel-Sellami M, et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol 2009; 161:522.</a></li><li><a class="nounderline abstract_t">Pavoni DP, Roxo VM, Marquart Filho A, Petzl-Erler ML. Dissecting the associations of endemic pemphigus foliaceus (Fogo Selvagem) with HLA-DRB1 alleles and genotypes. Genes Immun 2003; 4:110.</a></li><li><a class="nounderline abstract_t">Kricheli D, David M, Frusic-Zlotkin M, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000; 143:337.</a></li><li><a class="nounderline abstract_t">Parameswaran A, Attwood K, Sato R, et al. Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes. Br J Dermatol 2015; 172:729.</a></li><li><a class="nounderline abstract_t">Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67:869.</a></li><li><a class="nounderline abstract_t">Aoki V, Millikan RC, Rivitti EA, et al. Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc 2004; 9:34.</a></li><li><a class="nounderline abstract_t">Igawa K, Matsunaga T, Nishioka K. Involvement of UV-irradiation in pemphigus foliaceus. J Eur Acad Dermatol Venereol 2004; 18:216.</a></li><li><a class="nounderline abstract_t">Reis VM, Toledo RP, Lopez A, et al. UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris. J Am Acad Dermatol 2000; 42:571.</a></li><li><a class="nounderline abstract_t">Muramatsu T, Iida T, Ko T, Shirai T. Pemphigus vulgaris exacerbated by exposure to sunlight. J Dermatol 1996; 23:559.</a></li><li><a class="nounderline abstract_t">Kawana S, Nishiyama S. Involvement of membrane attack complex of complement in UV-B-induced acantholysis in pemphigus. Arch Dermatol 1990; 126:623.</a></li><li><a class="nounderline abstract_t">Tan SR, McDermott MR, Castillo CJ, Sauder DN. Pemphigus vulgaris induced by electrical injury. Cutis 2006; 77:161.</a></li><li><a class="nounderline abstract_t">Tur E, Brenner S. Contributing exogenous factors in pemphigus. Int J Dermatol 1997; 36:888.</a></li><li><a class="nounderline abstract_t">Brenner S, Tur E, Shapiro J, et al. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001; 40:562.</a></li><li><a class="nounderline abstract_t">Brenner S, Wohl Y. A burning issue: burns and other triggers in pemphigus. Cutis 2006; 77:145.</a></li><li><a class="nounderline abstract_t">Ruocco V, Pisani M. Induced pemphigus. Arch Dermatol Res 1982; 274:123.</a></li><li><a class="nounderline abstract_t">Ruocco V, Ruocco E, Lo Schiavo A, et al. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol 2013; 31:374.</a></li><li><a class="nounderline abstract_t">Inadomi T. A case of pemphigus foliaceus aggravated in an irradiated area by radiotherapy against breast cancer. Indian J Dermatol 2015; 60:93.</a></li><li><a class="nounderline abstract_t">Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol 1998; 16:393.</a></li><li><a class="nounderline abstract_t">Marsden RA, Vanhegan RI, Walshe M, et al. Pemphigus foliaceus induced by penicillamine. Br Med J 1976; 2:1423.</a></li><li><a class="nounderline abstract_t">Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol 2011; 29:455.</a></li><li><a class="nounderline abstract_t">Feng S, Zhou W, Zhang J, Jin P. Analysis of 6 cases of drug-induced pemphigus. Eur J Dermatol 2011; 21:696.</a></li><li><a class="nounderline abstract_t">Chen WS, Tetzlaff MT, Diwan H, et al. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. J Cutan Pathol 2018; 45:764.</a></li><li><a class="nounderline abstract_t">Mustafa MB, Porter SR, Smoller BR, Sitaru C. Oral mucosal manifestations of autoimmune skin diseases. Autoimmun Rev 2015; 14:930.</a></li><li><a class="nounderline abstract_t">Kavala M, Topaloğlu Demir F, Zindanci I, et al. Genital involvement in pemphigus vulgaris (PV): correlation with clinical and cervicovaginal Pap smear findings. J Am Acad Dermatol 2015; 73:655.</a></li><li><a class="nounderline abstract_t">Kavala M, Altıntaş S, Kocatürk E, et al. Ear, nose and throat involvement in patients with pemphigus vulgaris: correlation with severity, phenotype and disease activity. J Eur Acad Dermatol Venereol 2011; 25:1324.</a></li><li><a class="nounderline abstract_t">Memar O, Jabbehdari S, Caughlin B, Djalilian AR. Ocular surface involvement in pemphigus vulgaris: An interdisciplinary review. Ocul Surf 2020; 18:40.</a></li><li><a class="nounderline abstract_t">Torchia D, Romanelli P, Kerdel FA. Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus. J Am Acad Dermatol 2012; 67:417.</a></li><li class="breakAll">Amagai M. Pemphigus. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV, et al (Eds), Elsevier, 2012. Vol 1, p.461.</li><li><a class="nounderline abstract_t">Venugopal SS, Murrell DF. Diagnosis and clinical features of pemphigus vulgaris. Dermatol Clin 2011; 29:373.</a></li><li><a class="nounderline abstract_t">Yoshida K, Takae Y, Saito H, et al. Cutaneous type pemphigus vulgaris: a rare clinical phenotype of pemphigus. J Am Acad Dermatol 2005; 52:839.</a></li><li><a class="nounderline abstract_t">Shinkuma S, Nishie W, Shibaki A, et al. Cutaneous pemphigus vulgaris with skin features similar to the classic mucocutaneous type: a case report and review of the literature. Clin Exp Dermatol 2008; 33:724.</a></li><li><a class="nounderline abstract_t">Ohshima Y, Tamada Y, Matsumoto Y, Watanabe D. A case of cutaneous type pemphigus vulgaris. Int J Dermatol 2012; 51:1398.</a></li><li class="breakAll">Payne AS, Stanley JR. Pemphigus. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw Hill, 2012. Vol 1, p.586.</li><li><a class="nounderline abstract_t">Lebeau S, Müller R, Masouyé I, et al. Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype. Clin Exp Dermatol 2010; 35:366.</a></li><li><a class="nounderline abstract_t">Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J Am Acad Dermatol 1999; 40:649.</a></li><li><a class="nounderline abstract_t">Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol 2014; 70:780.</a></li><li><a class="nounderline abstract_t">Peterman CM, Vadeboncoeur S, Schmidt BA, Gellis SE. Pediatric Pemphigus Herpetiformis: Case Report and Review of the Literature. Pediatr Dermatol 2017; 34:342.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Yasumoto S, Nagata Y, et al. Clinical, histopathological and immunological distinction in two cases of IgA pemphigus. Clin Exp Dermatol 2002; 27:636.</a></li><li><a class="nounderline abstract_t">Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340:1406.</a></li><li><a class="nounderline abstract_t">Gushi M, Yamamoto Y, Mine Y, et al. Neonatal pemphigus vulgaris. J Dermatol 2008; 35:529.</a></li><li><a class="nounderline abstract_t">Zhao CY, Chiang YZ, Murrell DF. Neonatal Autoimmune Blistering Disease: A Systematic Review. Pediatr Dermatol 2016; 33:367.</a></li><li><a class="nounderline abstract_t">Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Coexistent Solid Malignancies in Pemphigus: A Population-Based Study. JAMA Dermatol 2018; 154:435.</a></li><li><a class="nounderline abstract_t">Chiu YW, Chen YD, Hua TC, et al. Comorbid autoimmune diseases in patients with pemphigus: a nationwide case-control study in Taiwan. Eur J Dermatol 2017; 27:375.</a></li><li><a class="nounderline abstract_t">Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association Between Pemphigus and Neurologic Diseases. JAMA Dermatol 2018; 154:281.</a></li><li><a class="nounderline abstract_t">Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Bipolar Disorder Associated with Another Autoimmune Disease-Pemphigus: A Population-based Study. Can J Psychiatry 2018; 63:474.</a></li><li><a class="nounderline abstract_t">Kridin K, Zelber-Sagi S, Comaneshter D, et al. Pemphigus and hematologic malignancies: A population-based study of 11,859 patients. J Am Acad Dermatol 2018; 78:1084.</a></li><li class="breakAll">Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier, 2010. p.123.</li><li><a class="nounderline abstract_t">Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159:2010.</a></li><li><a class="nounderline abstract_t">Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009; 145:529.</a></li><li><a class="nounderline abstract_t">Zone JJ. The value of desmoglein 1 and 3 antibody ELISA testing in patients with pemphigus. Arch Dermatol 2009; 145:585.</a></li><li><a class="nounderline abstract_t">Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010; 134:320.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Ebihara T, Nishikawa T. Studies of autoantigens recognized by IgA anti-keratinocyte cell surface antibodies. J Dermatol Sci 1996; 12:10.</a></li></ol></div><div id="topicVersionRevision">Topic 83684 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17521373" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Immunopathology and molecular diagnosis of autoimmune bullous diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16274453" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mechanisms of blister induction by autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16670756" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : T cell control in autoimmune bullous skin disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492232" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31293582" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pemphigus: Current and Future Therapeutic Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679872" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : IgA pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955378" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Autoimmune bullous skin diseases. Part 1: Clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29479654" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pemphigus group: overview, epidemiology, mortality, and comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895907" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Geoepidemiologic considerations of auto-immune pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752842" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638734" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endemic pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679871" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605805" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diagnosis and clinical features of pemphigus foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2642512" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Endemic pemphigus foliaceus (Fogo Selvagem): II. Current and historic epidemiologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17618167" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A survey of sex differences in 249 pemphigus patients and possible explanations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829889" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512903" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A unique form of endemic pemphigus in northern Colombia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065642" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29313220" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/564142" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epidermal acantholysis induced in vitro by pemphigus autoantibody. An ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/950490" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/701477" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pemphigus antibody interaction with human epidermal cells in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8481022" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The distribution of IgA pemphigus antigen in human skin and the role of IgA anti-cell surface antibodies in the induction of intraepidermal acantholysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7040962" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233765" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905977" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2247105" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2778350" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ultrastructural studies of acantholysis induced in vivo by passive transfer of IgG from endemic pemphigus foliaceus (Fogo Selvagem).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040292" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539469" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18386043" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The desmosome and pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20548314" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : From cell signaling to novel therapeutic concepts: international pemphigus meeting on advances in pemphigus research and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21939410" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pemphigus autoimmunity: hypotheses and realities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025740" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326396" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1522242" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7761479" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34265330" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Human Desmocollin 3‒Specific IgG Antibodies Are Pathogenic in a Humanized HLA Class II Transgenic Mouse Model of Pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2654636" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22803659" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Enrichment of total serum IgG4 in patients with pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35371083" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10021453" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22913529" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789199" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952584" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Autoimmunity to desmocollin 3 in pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21281804" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19456767" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Autoantibodies against desmocollins in European patients with pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20542173" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antidesmocollin-1 antibody-positive, antidesmoglein antibody-negative pemphigus herpetiformis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12705872" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10899159" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11021840" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120754" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545999" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705676" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Immunopathology of IgA pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242496" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405762" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Detection of IgA autoantibodies to desmogleins by an enzyme-linked immunosorbent assay: the presence of new minor subtypes of IgA pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27258999" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical and immunological studies of 49 cases of various types of intercellular IgA dermatosis and 13 cases of classical subcorneal pustular dermatosis examined at Kurume University.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1802908" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : IgA autoantibodies bind to pemphigus vulgaris antigen in a case of intraepidermal neutrophilic IgA dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176383" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10839721" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Identification of desmoglein 1 as autoantigen in a patient with intraepidermal neutrophilic IgA dermatosis type of IgA pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723725" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Immunolocalization of target autoantigens in IgA pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077468" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453789" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Anti-desmoglein 1 antibodies in healthy related and unrelated subjects and patients with pemphigus foliaceus in endemic and non-endemic areas from Tunisia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6936869" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : HLA-DRw4 in pemphigus vulgaris patients in Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1675792" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2888115" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Detection of disease-specific restriction fragment length polymorphisms in pemphigus vulgaris linked to the DQw1 and DQw3 alleles of the HLA-D region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2894075" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A newly characterized HLA DQ beta allele associated with pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9347787" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : HLA-DRB1*04 and DRB1*14 alleles are associated with susceptibility to pemphigus among Japanese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10417627" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2500728" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Are HLA class II genes controlling susceptibility and resistance to Brazilian pemphigus foliaceus (fogo selvagem)?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8284787" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Genetic markers for susceptibility to endemic Brazilian pemphigus foliaceus (Fogo Selvagem) in Xavante Indians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19486004" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618858" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dissecting the associations of endemic pemphigus foliaceus (Fogo Selvagem) with HLA-DRB1 alleles and genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10951142" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25272088" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1720352" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14870983" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009310" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Involvement of UV-irradiation in pemphigus foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727300" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8854590" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pemphigus vulgaris exacerbated by exposure to sunlight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2334182" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Involvement of membrane attack complex of complement in UV-B-induced acantholysis in pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610735" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pemphigus vulgaris induced by electrical injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466192" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Contributing exogenous factors in pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737449" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610730" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A burning issue: burns and other triggers in pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7165361" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Induced pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806154" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25657410" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A case of pemphigus foliaceus aggravated in an irradiated area by radiotherapy against breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9642533" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Drug-induced pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1009359" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pemphigus foliaceus induced by penicillamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679874" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Drug-induced pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21697060" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Analysis of 6 cases of drug-induced pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29943453" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26117595" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Oral mucosal manifestations of autoimmune skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26194705" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Genital involvement in pemphigus vulgaris (PV): correlation with clinical and cervicovaginal Pap smear findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21348898" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Ear, nose and throat involvement in patients with pemphigus vulgaris: correlation with severity, phenotype and disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31614200" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Ocular surface involvement in pemphigus vulgaris: An interdisciplinary review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22101216" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22101216" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605802" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Diagnosis and clinical features of pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858475" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cutaneous type pemphigus vulgaris: a rare clinical phenotype of pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18627395" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cutaneous pemphigus vulgaris with skin features similar to the classic mucocutaneous type: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21790548" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A case of cutaneous type pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21790548" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A case of cutaneous type pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874319" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10321591" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The new pemphigus variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24472428" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Pemphigus herpetiformis: from first description until now.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28523900" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pediatric Pemphigus Herpetiformis: Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472534" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Clinical, histopathological and immunological distinction in two cases of IgA pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228191" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The mechanism of respiratory failure in paraneoplastic pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18789074" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Neonatal pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086740" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Neonatal Autoimmune Blistering Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29453868" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Coexistent Solid Malignancies in Pemphigus: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28747284" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Comorbid autoimmune diseases in patients with pemphigus: a nationwide case-control study in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29453873" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Association Between Pemphigus and Neurologic Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29108425" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Bipolar Disorder Associated with Another Autoimmune Disease-Pemphigus: A Population-based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29198780" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pemphigus and hematologic malignancies: A population-based study of 11,859 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29198780" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Pemphigus and hematologic malignancies: A population-based study of 11,859 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9257868" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451496" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451505" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The value of desmoglein 1 and 3 antibody ELISA testing in patients with pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20015693" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8740455" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Studies of autoantigens recognized by IgA anti-keratinocyte cell surface antibodies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
